Structural Optimization and Structure–Activity Relationship of 1 H -Pyrazole-4-carboxylic Acid Derivatives as DNA 6mA Demethylase ALKBH1 Inhibitors and Their Antigastric Cancer Activity
Journal of Medicinal Chemistry · 12.09.2024 · 67 (17) · 15456-15475
DOI: 10.1021/acs.jmedchem.4c01072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.09.2024. Verfasst von Feng Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: AlkB Homolog 1, Histone H2a Dioxygenase, Stomach Neoplasms, Pyrazoles, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Sichuan University, West China Hospital, Sichuan University, National Key Research and Development Program of China.
Abstract (Originalsprache)
DNA N6-methyladenine (6mA) demethylase ALKBH1 plays an important role in various cellular processes. Dysregulation of ALKBH1 is associated with the development of some cancer types, including gastric cancer, implicating a potential therapeutic target. However, there is still a lack of potent ALKBH1 inhibitors. Herein, we report the discovery of a highly potent ALKBH1 inhibitor, 1H-pyrazole-4-carboxylic acid derivative 29. The structure-activity relationship of this series of compounds was also discussed. Because of the poor cell membrane permeability of 29, we prepared a prodrug of 29 (29E), which showed excellent cellular activities. In gastric cancer cell lines HGC27 and AGS, 29E treatment significantly increased the abundance of 6mA, inhibited cell viability, and upregulated the AMP-activated protein kinase (AMPK) signaling pathway. In addition, the hydrolysis product 29 showed high exposure in mice after administration of 29E. Collectively, this research provides a new potent ALKBH1 inhibitor, which could serve as a lead compound for subsequent drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
- New Cornerstone Science Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, China.
ORCID-Profile: Liang Xiong, Linli Li, Shengyong Yang
Förderung
- Sichuan University
- West China Hospital, Sichuan University
- National Key Research and Development Program of China
- China Postdoctoral Science Foundation
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Sichuan Provincial Science and Technology Support Program
- New Cornerstone Science Foundation
Zitieren
APA
Li, F., Xiong, L., Zhang, J., Guo, Y., Xu, K., Xiong, Z., Wang, Y., Ji, S., Tong, A., Li, L., & Yang, S. (2024). Structural Optimization and Structure–Activity Relationship of 1 H -Pyrazole-4-carboxylic Acid Derivatives as DNA 6mA Demethylase ALKBH1 Inhibitors and Their Antigastric Cancer Activity. Journal of Medicinal Chemistry, 67(17), 15456-15475. https://doi.org/10.1021/acs.jmedchem.4c01072
Vancouver
Li F, Xiong L, Zhang J, Guo Y, Xu K, Xiong Z, et al. Structural Optimization and Structure–Activity Relationship of 1 H -Pyrazole-4-carboxylic Acid Derivatives as DNA 6mA Demethylase ALKBH1 Inhibitors and Their Antigastric Cancer Activity. Journal of Medicinal Chemistry. 2024;67(17):15456-15475. doi:10.1021/acs.jmedchem.4c01072
BibTeX
@article{Li2024,
author = {Li, Feng and Xiong, Liang and Zhang, Jian and Guo, Yinping and Xu, Ke and Xiong, Zijie and Wang, Yuyang and Ji, Shanmian and Tong, Aiping and Li, Linli and Yang, Shengyong},
title = {Structural Optimization and Structure–Activity Relationship of 1 H -Pyrazole-4-carboxylic Acid Derivatives as DNA 6mA Demethylase ALKBH1 Inhibitors and Their Antigastric Cancer Activity},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {17},
pages = {15456--15475},
doi = {10.1021/acs.jmedchem.4c01072}
}
EUVIMED